











Pericardial tamponade 1 (0.5%) 0 0 0.37 1(0.2%)
Device embolization 0 3 (1.4%) 0 0.049# 3 (4.5%)
Long-term Complications
Thrombus formation 0 1 (0.5%) 11 (5%) 0.0001* 12 (1.8%)
Atrial fibrillation 8 (3.6%) 5 (2.3%) 27 (12.3%) 0.0001* 40 (6%)
Peripheral embolism 0 0 0 1 0
Non-neurological death 3 (1.4%) 4 (1.8%) 3 (1.4%) 0.90 10 (1.5%)
Recurrent Neurological Events
TIA 0 4 (1.8%) 6 (2.7%) 0.058* 10 (1.5%)
Stroke 2 (0.9%) 4 (1.8%) 6 (2.7%) 0.36 12 (1.8%)
Cerebral Death 1 (0.5%) 1 (0.5%) 1 (0.5%) 1 3 (0.5%)
Complete PFO-closure 220
(100%)
213 (96.8%) 219 (99.5%) 0.004# 652
(98.8%)
*this represents the p-value comparing the CardioCEAL-STARflex device to both, the
Amplatzer and the Helex device. There was no significant difference between the
Amplatzer and Helex device.
#this represents the p-value comparing the Helex device to both, the Amplatzer and the
CardioSEAL-STARflex device. There was no significant difference between the Amplatzer
and CardioSEAL-STARflex device.
Conclusions: The periprocedural and long-term neurological event rates are low
regardless of the device used. The recurrent neurological event rate was significantly
higher after CardioSEAL-STARflex than after Amplatzer or Helex implantation. This has
important implications regarding the interpretation of trials comparing PFO closure to
medical management.
TCT-772
Role Of Non-ECG Gated Contrast CT In Preventing Percutaneous Pulmonary
Valve Implantation-Related Coronary Compromise
Paul Dunne1, Oliver Monfredi2, Bernard Clarke1, Gerard Murphy1,
Vaikom Mahadevan1
1Manchester Royal Infirmary, Manchester, United Kingdom, 2University of
Manchester, Manchester, United Kingdom
Background: Percutaneous pulmonary valve implantation (PPVI) is a non-surgical
transcatheter treatment for right ventricular to pulmonary artery conduit dysfunction. One
of the rare but significant risks of this procedure is acute coronary occlusion following
valve deployment. Proximity of coronary arteries has previously been assessed using
time-consuming and costly ECG gated contrast CT scanning or MRI. We assessed the
utility of non-ECG gated contrast CT scanning as an alternative for assessing the coronary
position in patients planned to undergo PPVI.
Methods: We studied a series of 22 consecutive patients presenting to our institution for
PPVI. The underlying diagnoses of these patients varied. In all of the patients, we used the
rapid, highly-accessible and relatively cheap technique of non-ECG gated 32-slice
contrast CT to assess the relationship of the coronary arteries to the proposed site of PPVI
in 3 planes – axial, saggital and coronal. Patients were only subsequently selected for
PPVI if there was a distance of at least 3 mm between the main coronary vessels and
region of proposed valve deployment.
Results: The mean age of patients selected for PPVI was 26. Non-ECG gated contrast CT
scanning was found to be highly effective in detecting the position of the coronary arteries,
allowing coronary identification in the axial plane 93% of the time, saggital plane 87% of
the time and in the coronal plane 87% of the time. No patient experienced acute coronary
occlusion when the exclusion criteria of3 mm between proposed valve deployment site
and nearest distance of coronary artery was employed.
Conclusions: Non-ECG gated contrast CT is effective, rapid and cost-effective in
allowing coronary characterisation before PPVI. A distance of 3 mm between coronary
artery and valve implantation site seems to be a safe distance to avoid PPVI related
coronary occlusion. More studies are required to assess this in further detail.
TCT-773
Transcatheter closure of perimembranous ventricular septal defect with the
Amplatzer® Membranous VSD Occluder 2
Apostolos Tzikas1, Daniel Aguirre2, Daniel Velasco-Sanchez3, Xavier Freixa4,
Marcela Alburquenque5, Paul Khairy4, John Bass6, Juan Ramirez5,
Reda Ibrahim4, Joaquim Miro3
1St Luke’s Hospital of Thessaloniki, Thessaloniki, Greece, 2Hospital de Niños
Roberto del Rı´o, na, na, 3Hôpital Sainte-Justine, Montréal, QC, 4Montreal Heart
Institute, Montreal, QC, 5Corominas Hospital, na, na, 6Amplatz Children’s
Hospital, Minneapolis, MN
Background: Transcatheter closure of peri-membranous ventricular septal defects
(pmVSDs) has been associated with a significant risk of complete heart block, leading
most groups to abandon the technique. Our objective was to describe the initial world
experience of pmVSD closure with a newly designed occluder.
Methods: Patients with pmVSD underwent catheter closure using the Amplatzer®
Membranous VSD Occluder 2 (AGA – St Jude, Minneapolis, MN, USA).
Results: Nineteen patients from the 4 centers initially involved worldwide were
prospectively included and followed for at least 30 days (median 48, range 31 – 245 days).
Patients ranged in age from 1.4 to 62 years (median 6 years) and in weight from 9.3 to 96
kg (median 26 kg). The Qp/Qs ratio was (mean  SD) 1.9  1.6. The size of the defect
on left ventricular side was 9.9  3.5 mm (range 4.6 – 16 mm) and the orifice on right
ventricular side was 8.1 2.8 mm (range 3.9 – 14 mm) by echocardiography. Mean device
size was 9.4 2.4 mm (range 5 – 14 mm). An eccentric device was used in 9 patients (47%)
and a concentric device in 10 (53%). A device was successfully implanted in 18 patients
(95%). Procedural time was 122  39 min (range 60 – 207 min). There were no significant
procedural complications. Mild (0-2 mm) residual shunt was initially observed in 14 patients
(78%). At last follow-up, mild residual shunt was still observed in only 3 patients (17%). There
was no significant increase of aortic or tricuspid regurgitation. No patient showed any degree
of AV block, although one patient developed a left anterior fascicular block. Holter evaluation
was obtained in 13/18 patients, and was normal in all.
Conclusions: Transcatheter closure of pmVSD with the Amplatzer® pmVSD Occluder
2 is safe and effective. No conduction abnormalities or any other complications were
observed on short-term follow of this initial human series.
TCT-774
Ten Year Experience with Transcatheter Closure of Perimembranous
Ventricular Septal Defects Using the Amplatzer Asymmetric Perimembranous
Ventricular Septal Defect Occluder in Children
Vasileios Thanopoulos1, Andreas Giannopoulos2, George Tsaousis3
1Iatrikon Medical Center, Marousi-Athens, - E°´ -, 2Ahepa University
Hospital, Thessaloniki, Greece, 3Iatrikon Medical Center, Marousi-Athens, Greece
Background: In this report we present 10 year experience with 78 patients (pts) with
perimembranous ventricular septal defects (PMVSDs) who underwent transcatheter
closure at 5 different Institutions with the Amplatzer asymmetric PMVSD occluder.
Methods: The age of the pts ranged from 0.3 to 15 years. During the study period 35
other patients were excluded from transcatheter closure because they did not fulfil the
patient selection criteria (distance less than 2 mm from the PMVSD to the aortic valve,
size of VSD in relation to patients age).
Results: The devise was permanently implanted in 72/78 patients. Complete occlusion of
the communication at six month, one-year, and 2-year follow-up was observed in 93%, 97
%, and 97% patients, respectively. Main complications included: Early. Were observed in
patients less than one year (body weight  8 Kg) and included: a. Device embolization
(2 patients-catheter and surgical removal, respectively), b. severe procedural bradycardia
(5 pts) and c. Mobitz II and complete heart block heart in 3 and 1 patients respectively.
(sinus rhythm after device removal). Late (follow-up 6 months-10 years). Complete heart
block was developed in one patient 4-year old with Down syndrome. No other patient
developed heart block during the follow-up. Three patients developed mild aortic
regurgitation. In one of them the regurgitation was not seen at the 1-year follow-up. No
other complications were observed.
Conclusions: Transcatheter closure using the Amplatzer APMVSD occluder is as a safe
and effective nonsurgical alternative that should be offered in properly selected patients
with PMVSDs. It should be noted, however, that with the current design of the
occluder-delivery system the procedure carries an increased risk in small patients less than
one-year of age. Finally, due to anatomic reasons, this therapy cannot be offered to
significant number of patients with these defects.
TCT-775
Novel System for Detection of Cardiac Right to Left Shunts
Robert Sommer1, Russell Brandwein2, David Dobson3, Eric Eggers3,
Andrew Eggers3
1Columbia University Medical Center, New York, USA, 2Columbia Medical
Center, New York, NY, 3Cardiox Corporation, Columbus, OH
Background: The current “gold standard” for detection and quantification of right-to-left
shunts (RLS) is transesophageal echocardiography (TEE). The Flow Detection System (FDS)
(Cardiox Corp., Columbus, OH) is a new, minimally invasive, diagnostic test, based on
transdermal detection of Indocyanine Green (ICG) dye (Pulsion Medical Systems AG,
Munich, Germany). The present study was performed to determine optimum ICG dosing and
injection timing protocols, as well as the system’s accuracy in the detection of RLS.
Methods: Various ICG dosages and injection timing protocols were evaluated in eight
(8) patients, with known RLS, to determine the optimal dose and injection timing to
facilitate detection of RLS with FDS. 20 additional patients underwent testing with power
m-mode transcranial Doppler (TCD) and subsequent FDS. Ten (10) patients with large
RLS, (Spencer grades IV or V by TCD) were selected to comprise the study group. Ten
(10) additional patients with Spencer grades 0 or I shunt by TCD were selected to
comprise a control group. All patients were evaluated just prior to a scheduled
catheterization, with both TCD and FDS using the dosing and timing parameters
developed in the initial cohort of eight patients. In the study group, results were also
compared with RLS assessment by intra-cardiac echocardiography (ICE - Johnson &
Johnson, NJ) performed during the catheterization.
Results: All ten study subjects with TCD-proven RLS exhibited a Shunt Conductance
Index (SCI) 0, reflecting the presence of a RLS (sensitivity 100%). FDS was also in
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agreement with ICE results in all ten. Nine (9) of ten (10) patients with TCD-negative
RLS, had SCI  0.
Conclusions: The Cardiox FDS, with the established dosage of ICG dye and timing
protocols, provided consistent detection of significant RLS (Spencer Grades IV or V),
with a good negative predictive value.
TCT-776
UNES (Utah Nickel Elution Studies)
Muhammad Khan1, Anwar Tandar1, Div Verma1, Amit Patel2,
Rajasekaran Soorappan1, Joseph Muhlestein3, Rodney Badger1
1University of Utah School of Medicine, Salt Lake City, UT, 2Cardiovscular Regenerative
Medicine, Salt Lake City, USA, 3Intermountain Medical Center, Murray, UT
Background: Percutaneous closure of ASD/ PFO has become a common procedure.
Concerns exist regarding possible adverse outcomes with device implantation in patients
allergic to nickel. Quantifying nickel elution by various devices is important.
Methods: We compared nickel elution behavior of 4 devices- AGA Amplatzer®
Occluder “Cribriform” (AGA Medical Corporation; Plymouth, Minn), Gore GSO® and
Gore Helex® Septal Occluder (W.L.Gore & Associates, Flagstaff, AZ), Sternalwire, and
control-1xDulbecco’s Phosphate-Buffered Saline (DPBS). Three device samples from
each group were submerged in DPBS. Nickel elution was measured by blinded personal
using Plasma Mass Spectroscopy at 24hours (h), 48h, 72h then weekly to 60 days.
Results: Nickel elution was significantly higher for AGA device compared to control
group at all time points to 60 days (15.202.89 vs0.010mg/L, p.001,Figure1).
Individual group comparisons by Bonferroni Multiple Comparisons test showed that
nickel elution was statistically similar amongst devices other than AGA.
Conclusions: There is significant variability of Nickel elution among the intra-atrial
septal closure devices. AGA device has the greatest Nickel elution over 60 days. Clinical
significance of nickel elution needs to be evaluated in clinical studies.
TCT-777
Non-Cerebrovascular Systemic Arterial Embolic Events from Paradoxical
Embolization via Patent Foramen Ovale (PFO)
RONAN MARGEY1, RONAN MARGEY1, Sammy Elmariah2, Brian Hynes3,
Pablo Renfigo-Moreno3, Michael Jaff4, Robert Schainfeld5, Ignacio Inglessis6,
Igor Palacios7
1MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA, 2Massachusetts
General Hospital, Boston, MA, 3Massachusetts General Hosptial, BOSTON, MA,
4Harvard Medical School, Boston, USA, 5Harvard Medical School, Newton, USA,
6Massachusetts General Hospital, BOSTON, MA, 7Associate Professor of
Medicine. Harvard Medical School, Boston, USA
Background: Paradoxical cerebral embolic events via PFO are well described.The
frequency and impact of such embolization to other vascular beds is poorly defined.We
describe a single center cohort of patients presenting with non-cerebrovascular paradox-
ical emboli,evaluating the relationship between high-risk PFO echo features,previously
undiagnosed May-Thurner Syndrome,and hypercoagulability(cohort 1)compared to pa-
tients presenting with stroke(CVA)and/or transient ischemic attack(TIA)(cohort 2).
Methods: 801 patients who underwent transcatheter closure of PFO between 2001 and
2010 were retrospectively analyzed with clinical,procedural characteristics plus immedi-
ate and long-term follow-up recorded.Two-sided T tests and Fishers’Exact test and
Kaplan-Meier event free (death,cardiac death,CVA/TIA,arterial embolic event)survival
analysis were performed.
Results: 801 closures were performed.Cohort 1 included 29 PFO closures(3.5% of
total),with 6 acute myocardial infarctions (MI),9 retinal emboli,6 renal infarctions,3 radial
artery occlusions,3 splenic infarcts, and 2lower extremity arterial emboli.772 patients are
included in cohort 2.Cohort 1 had a higher incidence of May-Thurner
syndrome(p0.0005)and were more likely to have an atrial septal aneurysm(p
0.08).Procedural success was 100%.In-hospital 1 device embolization was successfully
retrieved,no other in-hospital complications occurred.Effective defect closure was 100%
with no significant residual shunting.Event-free survival in cohort 1 was 100%, median
follow-up of 12.1 months (IQR 4.7, 23.7) compared with 97.4%, median follow-up of
25.3 months(IQR 11.6, 57.8) in cohort 2.
Risk Factor Cohort 1 (N 29) Cohort 2 (N 772) p-Value
Age mean (SD) 48.0 (	/14) 49.9 (	/13.7) 0.8
Male Gender 50% 53.5% 0.8
Hypertension 33.3% 30.0% 0.8
Hyperlipidemia 47.6% 34.9% 0.3
Current or former Smoker 25.0% 34.2% 0.3
Family Hx of vascular
disease
0 10.4 0.1
Diabetes 4.2% 5.7% 0.7
Hypercoagulable Disorder 33.3% 27.5% 0.5
Echo Tunnel Length (mm) 8.2 (	/ 4.4) 11.1 (	/4.7) 0.9
Atrial Septal Aneursym 41.7% 25.5% 0.08
May-Thurner Syndrome 41.7% 15.1% 0.0005
Conclusions: This is the largest series of PFO associated non-CVA/TIA paradoxical
emboli,highlighting the need to screen for high risk PFO features and co-existantMay-
Thurner syndrome.These patients can be treated successfully with transcatheter closure,
with no recurrent events in follow-up.
TCT-778
Long-term Outcomes After Transcatheter Closure of Patent Foramen Ovale
Sammy Elmariah1, Ignacio Inglessis1, Pablo Rengifo1, Ronan Margey1,
Suzanne Baron2, Caitlin O’Callaghan1, Ignacio Cruz-Gonza´lez3,
Zareh Demirjian1, Ferdinando Buonanno1, MingMing Ning1, Scott Silverman1,
Eugene Pomerantsev1, Robert Schainfeld1, G. Dec1, Igor Palacios1
1Massachusetts General Hospital, Harvard Medical School, Boston, MA,
2Massachusetts General Hospital, MA, 3Hospital Universitario de Salamanca,
Salamanca, Castilla y Leon
Background: Percutaneous transcatheter closure of patent foramen ovale (PFO) is com-
monly performed for several indications despite conflicting data regarding the efficacy of this
intervention. We examined the indications for as well as the immediate and long-term
procedural outcomes of PFO closure in a large and diverse cohort of patients.
Methods: We report the outcomes of 801 consecutive patients (52% male, 5014 years)
who underwent PFO closure at our institution over a 13-year period after rigorous
multidisciplinary evaluation.
Results: Indications for closure included cryptogenic cerebrovascular event (93%), hypox-
emia (2%), peripheral embolism (3%), and other (2%). Procedural success was 99% with
effective closure obtained in 95% of patients. At a mean follow-up of 3635 months, 20
patients sustained a recurrent neurologic event (6 strokes, and 14 transient ischemic attacks) for
a cumulative incidence rate of 0.83% per year (Figure). Only Eustachian valve prominence
(hazard ratio (HR)12.5 (95% confidence interval: 3.56–43.6); p-value0.0001) and
moderate or severe residual shunt after closure (HR5.36 versus no or trace shunt (95%CI:
1.21–23.85); p-value0.03) were associated with neurologic events.
Conclusions: Transcatheter closure of PFO is safe and feasible in patients with several
clinical indications. The efficacy of this intervention in patients with paradoxical
embolism appears superb in this long-term observational study. Carefully selected patients
with features suggestive of paradoxical embolism are the most likely to benefit from PFO
closure and should be the focus of future investigation.
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